Le Lézard
Classified in: Business
Subject: STR

IIROC Trading Resumption - DMGI


VANCOUVER, Feb. 13, 2018 /CNW/ - Trading resumes in:

Company: DMG Blockchain Solutions Inc.

TSX-Venture Symbol: DMGI

Resumption (ET): 2:00 PM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions


These press releases may also interest you

at 08:05
Cutera, Inc. ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 9, 2024....

at 08:05
The Beauty Health Company , home to flagship brand Hydrafacialtm, today announced it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. The Company will host an investor conference call at 4:30 p.m. Eastern...

at 08:05
Bragg Gaming Group Inc. ( NASDAQ: BRAG , TSX: BRAG ) (" Bragg " or the " Company"), a global B2B gaming technology and content provider, announced today that it will release its first quarter 2024 financial results prior to the opening of the...

at 08:05
Piper Sandler Companies has released its most recent financial results. The complete earnings release can be found on the firm's website at pipersandler.com/earnings Join the earnings conference call on Friday, April 26, 2024 at 8:00 a.m. CT....

at 08:05
CPI Card Group Inc. ("CPI Card Group"), a payments technology company and leading provider of credit, debit, and prepaid card and digital solutions, including Software-as-a-Service-based instant issuance, today announced it will host a webcast and...

at 08:05
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage...



News published on and distributed by: